secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verastem, Inc. (VSTM)
CIK:        0001526119
Form:       8-K
Filed at:   2026-01-08T23:59:59+00:00
Accession:  0001104659-26-002135
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Verastem provides pipeline update; Q3 net product revenue $11.2M; cash runway into 1H2027
--------------------------------------------------------------------------------

- AVMAPKI FAKZYNJA CO-PACK launch momentum: $11.2M net product revenue Q3 2025, 133 prescribers.
- Phase 3 RAMP 301 trial fully accrued; topline PFS data expected mid-2027.
- VS-7375 KRAS G12D inhibitor: cleared 900 mg QD dose no DLTs; FDA FTD in PDAC.
- Pipeline milestones: RAMP 205 update 1H2026; VS-7375 monotherapy expansion cohorts 1H2026.
- Extended cash runway into 1H2027 via Oberland debt refinancing and equity investment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1526119/000110465926002135/0001104659-26-002135-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1526119/000110465926002135/tm262531d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-002135

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer